Basic pharmaceutical product manufacturing is an integral part of the pharmaceutical supply chain and the pharmaceutical sector's research and development process. Over the five years through 2023-24, industry revenue is expected to increase at a compound annual rate of 5.6% to reach £2.9 billion, including forecast growth of 6.2% in 2023-24. Sales have been supported by pharma companies modernising their manufacturing processes and rationalising their product portfolios. Despite this, many multinationals have continued to offshore production to developing countries with lower costs, holding revenue back.Strong treatment: The ageing UK population continues to drive up demand for pharmaceuticals
Companies in the Basic Pharmaceutical Product Manufacturing industry manufacture medicinal active substances that are used for their pharmacological properties to make medications, including antibiotics, basic vitamins, salicylic acids and aspirin. The industry also includes companies that manufacture chemically pure sugars and process blood and glands.
This report covers the scope, size, disposition and growth of the industry including the key sensitivities and success factors. Also included are five year industry forecasts, growth rates and an analysis of the industry key players and their market shares.
Table of Contents
ABOUT THIS INDUSTRY- Industry Definition
- Main Activities
- Similar Industries
- Additional Resources
INDUSTRY PERFORMANCE
- Executive Summary
- Key External Drivers
- Current Performance
- Industry Outlook
- Industry Life Cycle
- Supply Chain
- Products & Services
- Major Markets
- Globalisation & Trade
- Business Locations
- Market Share Concentration
- Key Success Factors
- Cost Structure Benchmarks
- Barriers to Entry
OPERATING CONDITIONS
- Capital Intensity
- Industry Data
- Annual Change
- Key Ratios
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AstraZeneca UK Ltd
Methodology
LOADING...